Cargando…

Translational predictions of phase 2a first-in-patient efficacy studies for antituberculosis drugs

BACKGROUND: Phase 2a trials in tuberculosis typically use early bactericidal activity (EBA), the decline in sputum CFU over 14 days, as the primary end-point for testing the efficacy of drugs as monotherapy. However, the cost of phase 2a trials can range from USD 7 million to USD 19.6 million on ave...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ernest, Jacqueline P., Goh, Janice Jia Ni, Strydom, Natasha, Wang, Qianwen, van Wijk, Rob C., Zhang, Nan, Deitchman, Amelia, Nuermberger, Eric, Savic, Rada M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2023
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469274/ https://www.ncbi.nlm.nih.gov/pubmed/37321622 http://dx.doi.org/10.1183/13993003.00165-2023

Ejemplares similares

Mechanistic Modeling of Mycobacterium tuberculosis Infection in Murine Models for Drug and Vaccine Efficacy Studies
por: Zhang, Nan, et al.
Publicado: (2020)

Quantification of Natural Growth of Two Strains of Mycobacterium Marinum for Translational Antituberculosis Drug Development
por: Van Wijk, Rob C., et al.
Publicado: (2020)

Pharmacodynamic Correlates of Linezolid Activity and Toxicity in Murine Models of Tuberculosis
por: Bigelow, Kristina M, et al.
Publicado: (2020)

New Paradigm for Translational Modeling to Predict Long‐term Tuberculosis Treatment Response
por: Bartelink, IH, et al.
Publicado: (2017)

Clinical impact of plasma concentrations of first-line antituberculosis drugs
por: Perumal, R, et al.
Publicado: (2023)

Model-Based Efficacy and Toxicity Comparisons of Moxifloxacin for Multidrug-Resistant Tuberculosis
por: Yun, Hwi-Yeol, et al.
Publicado: (2021)

Current research toward optimizing dosing of first-line antituberculosis treatment
por: McIlleron, Helen, et al.
Publicado: (2018)

First-Line Antituberculosis Drug Concentrations in Infants With HIV and a History of Recent Admission With Severe Pneumonia
por: Chabala, Chishala, et al.
Publicado: (2023)

Acquired Resistance to Antituberculosis Drugs
por: Aung, Htin Lin, et al.
Publicado: (2018)

Antituberculosis drug-induced hepatotoxicity in children
por: Donald, Peter R
Publicado: (2011)

Population Pharmacokinetics of the Antituberculosis Agent Pretomanid
por: Salinger, David H., et al.
Publicado: (2019)

Diagnosis of Hypersensitivity Induced by Antituberculosis Drugs
por: Wu, Yuqing, et al.
Publicado: (2021)

Anaphylactic Shock After First-Line Treatment With Antituberculosis Drugs in a Patient With Lupus
por: Charii, Hajar, et al.
Publicado: (2023)

The Risk of Treating Populations Instead of Patients
por: Deitchman, Amelia N.
Publicado: (2019)

Mycobacterium tuberculosis resistance to antituberculosis drugs in Mozambique,
por: Pires, Germano Manuel, et al.
Publicado: (2014)

The impact of immune disturbances on the failure of antituberculosis treatment
por: LESNIC, EVELINA, et al.
Publicado: (2016)

Empyema Necessitans due to Interruption of Antituberculosis Treatment
por: Benaragama, H. N., et al.
Publicado: (2019)

Suboptimal Antituberculosis Drug Concentrations and Outcomes in Small and HIV‐Coinfected Children in India: Recommendations for Dose Modifications
por: Guiastrennec, Benjamin, et al.
Publicado: (2018)

The Effect of an Antituberculosis Serum on the Development of Experimental Tuberculosis of the Skin
por: Thomas, Robert M., et al.
Publicado: (1940)

Barriers to Initiation of Antiretrovirals during Antituberculosis Therapy in Africa
por: Pepper, Dominique J., et al.
Publicado: (2011)

The Chemical Components of Sesbania grandiflora Root and Their Antituberculosis Activity
por: Hasan, Noviany, et al.
Publicado: (2012)

Antituberculosis: Synthesis and Antimycobacterial Activity of Novel Benzimidazole Derivatives
por: Keng Yoon, Yeong, et al.
Publicado: (2013)

Adverse Reactions to Antituberculosis Drugs in Iranian Tuberculosis Patients
por: Farazi, Aliasghar, et al.
Publicado: (2014)

Risk factors associated with adverse reactions to antituberculosis drugs
por: Resende, Laíse Soares Oliveira, et al.
Publicado: (2015)

The role of exogenous risk factors of antituberculosis treatment failure
por: LESNIC, EVELINA, et al.
Publicado: (2016)

Seizures following Intoxication with a Common Antituberculosis Drug
por: Lahlou, Adnane, et al.
Publicado: (2019)

Aureolic Acid Group of Agents as Potential Antituberculosis Drugs
por: Bespyatykh, Julia, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Intensive Antituberculosis Treatment of Tuberculous Meningitis
por: Ding, Junjie, et al.
Publicado: (2020)

Epidemiology of tuberculosis and susceptibility to antituberculosis drugs in Reunion Island
por: Loukman, Moreea, et al.
Publicado: (2023)

Pattern of drug resistance of Mycobacterium tuberculosis clinical isolates to first-line antituberculosis drugs in pulmonary cases
por: Kalo, Deepika, et al.
Publicado: (2015)

Impact of a Shortage of First-Line Antituberculosis Medication on Tuberculosis Control — United States, 2012–2013
por: Warkentin, Jon, et al.
Publicado: (2013)

Variations of Serum Oxidative Stress Biomarkers under First-Line Antituberculosis Treatment: A Pilot Study
por: Meca, Andreea-Daniela, et al.
Publicado: (2021)

First case of pulmonary tuberculosis and visceral leishmaniasis coinfection successfully treated with antituberculosis drug and liposomal amphotericin B
por: Hasnain, Md Golam, et al.
Publicado: (2014)

New Antituberculosis Drugs: From Clinical Trial to Programmatic Use
por: Gualano, Gina, et al.
Publicado: (2016)

Impact of combination antiretroviral therapy initiation on adherence to antituberculosis treatment
por: Knight, Marlene, et al.
Publicado: (2015)

Biosynthetic and Synthetic Strategies for Assembling Capuramycin-Type Antituberculosis Antibiotics
por: Biecker, Ashley L., et al.
Publicado: (2019)

Association of PXR and CAR Polymorphisms and Antituberculosis Drug-Induced Hepatotoxicity
por: Wang, Yu, et al.
Publicado: (2019)

Syntheses and evaluation of multicaulin and miltirone-like compounds as antituberculosis agents
por: Burmaoğlu, Serdar, et al.
Publicado: (2017)

A National Department of Public Health in Relation to the Antituberculosis Problem
por: Reed, Charles A. L.
Publicado: (1908)

Adverse drug reaction profile of daily regimen antituberculosis treatment
por: Sankar, K. N. Hari, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_r7kat51f3g8p5bvhe4o2c95s6h